Company Analysis AcelRx Pharmaceuticals, Inc.
1. Summary
Advantages
- Price (1.13 $) is less than fair price (1.21 $)
- The stock's return over the last year (0%) is higher than the sector average (-3.76%).
Disadvantages
- Dividends (0%) are below the sector average (0.5317%).
- Current debt level 50.99% has increased over 5 years from 38.61%.
- The company's current efficiency (ROE=-72.93%) is lower than the sector average (ROE=109.03%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| AcelRx Pharmaceuticals, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -13.3% | -0.6% |
| 90 days | 0% | -1.6% | 2.9% |
| 1 year | 0% | -3.8% | 21% |
ACRX vs Sector: AcelRx Pharmaceuticals, Inc. has outperformed the "Healthcare" sector by 3.76% over the past year.
ACRX vs Market: AcelRx Pharmaceuticals, Inc. has significantly underperformed the market by -20.99% over the past year.
Stable price: ACRX is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ACRX with weekly volatility of 0% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (1.13 $) is lower than the fair price (1.21 $).
Price not significantly lower than the fair price: The current price (1.13 $) is slightly lower than the fair price by 7.1%.
5.2. P/E
P/E vs Sector: The company's P/E (0.3211) is lower than that of the sector as a whole (33.49).
P/E vs Market: The company's P/E (0.3211) is higher than that of the market as a whole (-68.72).
5.2.1 P/E Similar companies
5.3. P/BV
P/BV vs Sector: The company's P/BV (159.78) is lower than that of the sector as a whole (260.15).
P/BV vs Market: The company's P/BV (159.78) is higher than that of the market as a whole (51.39).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (3461.86) is higher than that of the sector as a whole (129.83).
P/S vs Market: The company's P/S indicator (3461.86) is higher than that of the market as a whole (148.63).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-133.1) is lower than that of the sector as a whole (-28.84).
EV/Ebitda vs Market: The company's EV/Ebitda (-133.1) is lower than that of the market as a whole (-95.22).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -14.14% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-14.14%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-598.11%).
6.4. ROE
ROE vs Sector: The company's ROE (-72.93%) is lower than that of the sector as a whole (109.03%).
ROE vs Market: The company's ROE (-72.93%) is lower than that of the market as a whole (-6.23%).
6.6. ROA
ROA vs Sector: The company's ROA (-50.44%) is lower than that of the sector as a whole (-2.42%).
ROA vs Market: The company's ROA (-50.44%) is lower than that of the market as a whole (38.59%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0.8343%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.66%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5317%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
